Sex differences in brain atrophy in multiple sclerosis by Voskuhl, R.R. et al.
RESEARCH Open Access
Sex differences in brain atrophy in multiple
sclerosis
Rhonda R. Voskuhl1* , Kevin Patel1, Friedemann Paul2,3, Stefan M. Gold4,5, Michael Scheel6, Joseph Kuchling2,3,7,
Graham Cooper2,3,7,8, Susanna Asseyer2,3, Claudia Chien2,3,9, Alexander U. Brandt3,7, Cassandra Eve Meyer1 and
Allan MacKenzie-Graham1
Abstract
Background: Women are more susceptible to multiple sclerosis (MS) than men by a ratio of approximately 3:1.
However, being male is a risk factor for worse disability progression. Inflammatory genes have been linked to
susceptibility, while neurodegeneration underlies disability progression. Thus, there appears to be a differential
effect of sex on inflammation versus neurodegeneration. Further, gray matter (GM) atrophy is not uniform across
the brain in MS, but instead shows regional variation. Here, we study sex differences in neurodegeneration by
comparing regional GM atrophy in a cohort of men and women with MS versus their respective age- and sex-
matched healthy controls.
Methods: Voxel-based morphometry (VBM), deep GM substructure volumetry, and cortical thinning were used to
examine regional GM atrophy.
Results: VBM analysis showed deep GM atrophy in the thalamic area in both men and women with MS, whereas
men had additional atrophy in the putamen as well as in localized cortical regions. Volumetry confirmed deep GM
loss, while localized cortical thinning confirmed GM loss in the cerebral cortex. Further, MS males exhibited worse
performance on the 9-hole peg test (9HPT) than MS females. We observed a strong correlation between thalamic
volume and 9HPT performance in MS males, but not in MS females.
Conclusion: More regional GM atrophy was observed in men with MS than women with MS, consistent with
previous observations that male sex is a risk factor for worse disease progression.
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Introduction
Females are more susceptible to multiple sclerosis (MS) than
males, with a ratio of approximately 3:1 [1–3]. Increased sus-
ceptibility of females occurs in many autoimmune diseases,
suggestive of a fundamental sex-dependent immune mech-
anism as its etiology [4, 5]. Women have more robust im-
mune responses to self and foreign antigens as compared to
men, and this sex difference is observed across species [6, 7].
Sex differences can be due to sex hormones, sex chromo-
somes, or both [5]. Sex hormone effects on the immune
response in MS and its animal models have been widely doc-
umented in the literature [8–10]. A sex chromosome effect
on immune responses has been observed in MS models,
where the XX genotype conferred a more pro-inflammatory
response than the XY genotype [11, 12]. Finally, the female
to male ratio in MS has increased in the past decades [1],
likely due to gene-environment interactions [5].
Consistent with the importance of sex as a biological
variable [13], there are sex differences not only in the
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immune system but also in the brain [14]. Healthy male
brains are known to be significantly larger than those of
females, and there are regional differences in substruc-
ture volumes that persist, even when accounting for dif-
ferences in brain size [15–18]. Sex differences in the
brain are observed across species from humans to mice
[19–21].
The effect of sex appears to differ in the immune sys-
tem versus the central nervous system (CNS) in MS [4,
5], since women are more susceptible to disease, but
men are at higher risk for worse disability [22–25]. In a
very large natural history study in relapsing-remitting
MS (RRMS), men also demonstrated a shorter time to
conversion to secondary progressive MS (SPMS) [26].
Together, these studies suggest the possibility that MS
men may have a more severe neurodegenerative re-
sponse to inflammatory attacks [5].
Brain atrophy, specifically gray matter (GM) atrophy,
serves as a putative surrogate for neurodegeneration in
MS. Regional differences in GM atrophy have been
shown in MS, and clinical disabilities have been shown
to correlate with GM atrophy in clinically eloquent neu-
roanatomic regions [27–31]. Regional differences in gene
expression in astrocytes, microglia, and oligodendrocytes
have also been shown in both health and disease [32–
35], including a sex-specific astrocytic response to injury
in an MS model [36]. Given the regional heterogeneity
of the brain, we hypothesized that being female or male
may show regional differences in GM atrophy in the
brain during MS.
Here, sex differences in regional GM atrophy in MS
were evaluated using a cohort of female and male MS sub-
jects with age- and sex-matched healthy controls to reveal
insights relevant to sex differences in neurodegeneration.
Methods
Patients
For this retrospective cross-sectional study, we screened
data from 114 MS patients participating between July
2014 and August 2018 in an ongoing observational study
at the NeuroCure Clinical Research Center at the Char-
ité – Universitätsmedizin Berlin (VIMS study; EA1/163/
12). Inclusion criteria were a minimum age of 18 years
and the fulfillment of the 2010 McDonald criteria for
MS [37]. Patients were excluded if they had a history of
neurological diseases (other than MS), primary progres-
sive MS, or were missing brain MRI data. We included
89 MS patients (RRMS: 79, SPMS: 10) in the study. We
included 45 age- and sex-matched healthy controls
(HCs) who had an imaging assessment from our imaging
research database. Altogether, 134 subjects were in-
cluded in this study, with 89 MS (52 females and 37
males) and 45 healthy controls (28 females and 17
males). Female MS subtype was 87% (45) RRMS, 10% (5)
SPMS, and data was unavailable for 4% (2), whereas
male MS subtype was 81% (30) RRMS, 14% (5) SPMS,
and data was unavailable for 5% (2). Within female MS
patients, 27% (14) were not on any disease-modifying
treatment (DMT), 71% (37) were on a DMT (8 dimethyl
fumarate, 7 fingolimod, 9 glatiramer acetate, 11 inter-
feron beta, 2 teriflunomide), and data was unavailable
for 2% (1). Within male MS patients, 22% (8) were not
on any DMT, 70% (26) were on a DMT (3 dimethyl fu-
marate, 8 fingolimod, 3 glatiramer acetate, 3 interferon
beta, 1 natalizumab, 8 teriflunomide), and data was un-
available for 8% (3). Regarding the potential contribution
of comorbidities, only 1 patient was obese, 1 was a
smoker, and none were diabetic. Hypertension was ob-
served in 11 MS patients (6 female and 5 male) and 1
healthy control (male). All participants provided written
informed consent prior to their inclusion in the study.
The study was approved by the local ethics committee
and was performed in accordance with the Declaration
of Helsinki in its currently applicable version.
Clinical testing
Patients were examined under supervision of a board-
certified neurologist at the NeuroCure Clinical Research
Center, Charité – Universitätsmedizin Berlin to obtain
the Expanded Disability Status Scale (EDSS) score [38].
Standardized walking and upper extremity function were
assessed using two trials of the timed 25-foot walk
(T25FW) and two trials of the 9-hole peg test (9HPT)
per hand, respectively. To test cognitive processing
speed, the Symbol Digit Modalities Test (SDMT) was
completed according to manual protocol (Smith, A.,
SDMT manual, Los Angeles, CA, USA: Western Psycho-
logical Services) using the oral form (as opposed to the
written form) to eliminate the impact of fine or gross
motor impairments on SDMT performance.
MRI acquisition and image processing
All MRI data were acquired on the same 3T scanner
(MAGNETOM Tim Trio Siemens, Erlangen, Germany)
using a 3D high-resolution T1-weighted magnetization
prepared rapid acquisition gradient echo (MPRAGE) se-
quence (TR/TE/TI = 1900/3.03/900 ms, FOV = 240 × 240
mm2, matrix 240 × 240, 176 slices, 1 × 1 × 1 mm3 reso-
lution), as well as a 3D high-resolution fluid-attenuated in-
version recovery sequence (FLAIR) (TR/TE/TI = 6000/
388/2100 ms; FOV = 256 × 256 mm2, 1 × 1 × 1 mm3 reso-
lution). T2-hyperintense white matter lesion segmentation
for total lesion volume was semi-automatically performed
on 3D FLAIR images of all subjects using the MATLAB
SPM12 Lesion Segmentation Toolbox (LST) [39] lesion
growth algorithm and manually checked and edited by
two expert raters under the supervision of a board-
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certified radiologist (M.S.) using ITK-SNAP [40, 41].
Raters were blinded to sex, but not MS status.
Lesion in-painted MPRAGE images were processed in
MATLAB (The MathWorks, Natick, MA) and examined
with SPM12 [42] and the computational anatomy tool-
box (CAT-12) [43], using an approach similar to that de-
scribed previously [31]. In brief, the in-painted images
were tissue classified into gray matter (GM), white mat-
ter (WM), and cerebrospinal fluid (CSF) and registered
to MNI space using linear and non-linear transforma-
tions. The GM and WM segments were modulated for
non-linear components of the transformation. This re-
sulted in voxel-wise comparability between the subjects
while correcting for differences in whole brain size. The
GM segments were then smoothed with a Gaussian ker-
nel (8 mm FWHM) for VBM. The statistical parametric
maps generated by VBM are the result of statistical ana-
lyses conducted across the entire brain at a voxelwise
level comparing all the female MS patients to all the fe-
male healthy controls and all the male MS patients to all
the male healthy controls. All analyses were covaried for
age and intracranial volume and the statistical paramet-
ric maps were corrected for voxel-wise multiple compar-
isons by controlling the false discovery rate (FDR) [44]
at p = 0.05. GM, WM, and brain parenchymal fraction
(BPF = GM + WM) volumes were computed as the sum
of all voxel-wise volumes within spatially normalized
and modulated GM and WM segments.
Subcortical structure volumes (thalamus and putamen)
were quantified using the FreeSurfer software package
version 6.0.1 segmentation pipeline [45, 46]. Cortical
surface reconstruction was performed using a semi-
automated approach [47]. To assess sex-specific cortical
thickness differences between patients with MS and
HCs, we then performed male and female vertex-wise
analyses using a general linear model controlling for the
effect of age. Two independent analyses compared thick-
ness in (1) MS females vs. healthy females, and (2) MS
males vs. healthy males. To control for multiple compar-
isons, we employed a cluster-wise correction using a
Monte Carlo simulation with a p value set at < 0.05 [48].
Statistical analysis
We summarized subject characteristics using descriptive
statistics and compared both male and female MS pa-
tients and HCs using unpaired, heteroscedastic two-
tailed t tests. Heteroscedastic tests were performed to
account for differences in the variability of the measured
variables between MS patients and healthy controls.
Chi-squared test was used to test for differences in dis-
ease modifying treatment and MS subtype within the
different sexes. FreeSurfer subcortical volumes, GM,
WM, and BPF volumes between female HCs and female
MS patients and between male HCs and male MS
patients were compared using unpaired, heteroscedastic
two-tailed t tests corrected for intercranial volume. The
statistician was blinded to sex, but not MS status. p
values for imaging analyses were adjusted for multiple
comparisons by controlling for the false discovery rate
(FDR) [49]. Effect sizes were calculated as Hedge’s g,
interpreted as g > 0.20 (small effect); g > 0.50 (medium
effect); and g > 0.80 (large effect). 9HPT, T25FW, and
SDMT between female MS patients and male MS pa-
tients were also compared using unpaired, heteroscedas-
tic two-tailed t tests. Pearson’s correlations (corrected
for intracranial volume) between 9HPT and deep gray
structure volumes were found by conducting linear re-
gression analyses in R [50]. p values for clinical evalua-
tions and correlations were adjusted for multiple
comparisons by using the Bonferroni correction.
Results
Patient descriptive characteristics
A total of 89 MS (52 females and 37 males) and 45
healthy control (28 females and 17 males) brain MRIs
were analyzed. There were no differences between MS
female and MS male subjects (Table 1) in mean age,
duration of disease since diagnosis, or composite disabil-
ity scores, as measured by the EDSS. There were also no
differences in T2-hyperintense (FLAIR) white matter
lesion counts or volumes and no differences in the pro-
portion on disease modifying treatments or MS subtype
(see methods). There was also no difference in age be-
tween MS females versus healthy females and MS males
versus healthy males.
Voxel-based morphometry to detect regional GM atrophy
in MS females and MS males
A biology-driven approach, namely voxel-based morph-
ometry, showed deep GM loss in the thalamic region in
MS females (Fig. 1a, b) and in MS males (Fig. 1d,e), each
as compared to their respective age- and sex-matched
HCs. In addition, MS males showed significance clusters
of GM loss in the putamen, precuneus, and medial
frontal cortex (Fig. 1d ,e), which were more pronounced
than that in MS females (Fig. 1a, b).
Quantification of atrophy of deep GM substructures in MS
females and MS males
Based on the voxel-based morphometry findings (Fig. 1),
deep GM substructure volumes were determined using
FreeSurfer (Table 2). Consistent with voxel-based
morphometry data, decreased thalamic volume was ob-
served in MS females and MS males as compared to
their respective healthy age- and sex-matched controls.
This finding is consistent with previous observations of
thalamic atrophy occurring early in MS [51–54]. Not-
ably, MS males had more atrophy in the thalamus and
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putamen than MS females, each as compared to their re-
spective HCs.
Cortical thinning in MS females and MS males
Regional cortical thinning was determined using Free-
Surfer. Cortical thinning was observed in MS males, but
not in MS females, each as compared to their respective
HCs (Fig. 1c, f). The cortical thinning in MS males local-
ized to the right intraparietal sulcus (IPS) (Fig. 1f, white
arrow), a region known to be a core part of the dorsal
attention network (frontoparietal connectivity between
the frontal eye fields anteriorly and the intraparietal sul-
cus posteriorly) which is responsible for sustained, se-
lective, executive attention [55, 56], as well as the middle
occipital gyrus which is involved in visual spatial atten-
tion (Fig. 1f, yellow arrow) [55, 57].
Gray matter, white matter, and brain parenchymal
fraction volumes in MS females and MS males
GM, WM, and brain parenchymal fraction (BPF) vol-
umes were measured in MS females and MS males, each
as compared to their respective HCs (Table 2). GM vol-
umes were each significantly decreased by approximately
5% in both sexes. WM volumes were significantly de-
creased in MS females, while a decrease in WM volume
in MS males did not reach significance. BPF volumes
were each significantly decreased in both MS females
and MS males.
Clinical disability scores in MS females and MS males
MS males had worse upper extremity function as shown
by significantly worse performance on the 9HPT than
MS females (Table 3). We did not observe a difference
between MS male and MS female walking speeds, as
assessed by the T25FW. There was also no difference in
cognitive processing speed performance, as measured by
the oral form of the SDMT.
Correlations between 9HPT and subcortical GM volumes
When MS female and male data were pooled, we ob-
served a statistically significant inverse correlation be-
tween performance on the 9HPT and thalamic volume
(Table 4). Since increased 9HPT times indicate worse
performance, this result suggests that worse perform-
ance correlates with smaller thalami. Importantly, when
examined separately in each sex, male MS patients ex-
hibited a significant inverse correlation between per-
formance on the 9HPT and thalamic volume, whereas
female MS patients did not.
Similarly, when MS female and MS male data were
pooled, we observed an inverse correlation between per-
formance on the 9HPT and the putamen volume. Again,
Table 1 Descriptive characteristics










Mean ± SD (years) 42.1 ± 12.4 40.7 ± 11.7 0.60 38.2 ± 12.5 37.2 ± 15.7 0.83
Median, IQR 42.3, 31.8–50.7 40.0, 32.0–49.7 35.3, 29.7–44.0 30.5, 26.1–40.6
Range 18.1-66.8 20.3-64.1 20.5–69.0 21.5–68.3
Duration of MS (from Dx)
Mean ± SD (years) 8.5 ± 7.7 8.5 ± 6.8 1.00 n/a n/a n/a
Median, IQR 5.9, 1.9–14.5 7.3, 2.2–13.0 n/a n/a
Range 0.3-28.6 0.0-23.9 n/a n/a
EDSS
Mean ± SD 2.4 ± 1.4 2.3 ± 1.5 1.00 n/a n/a n/a
Median, IQR 2.0, 1.5–3.0 2.0, 1.0–3.0 n/a n/a
Range 0–6.5 0–6.0 n/a n/a
T2-hyperintense (FLAIR) white matter lesion count
Mean ± SD 33.9 ± 22.7 35.1 ± 25.4 0.83 4.4 ± 7.1 6.9 ± 12.0 0.43
Median, IQR 35, 14.8–48 30, 17-48 2, 0–4.3 1, 0–6
Range 2–107 0-128 0–30 0–43
T2-hyperintense (FLAIR) white matter lesion volume
Mean ± SD (cc) 8.1 ± 10.8 8.1 ± 8.2 0.98 0.3 ± 0.5 1.0 ± 3.5 0.39
Median, IQR 4.8, 1.2–10.5 5.7, 1.9–11.4 0.1, 0.0–0.2 0.0, 0.0–0.2
Range 0.1–50.0 0.0–31.8 0.0–2.0 0.0–14.6
Descriptive characteristics of the MS and healthy control populations
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when examined in each sex, male MS patients exhibited
a trend toward an inverse correlation between perform-
ance on the 9HPT and putamen volume, whereas female
MS patients did not.
Discussion
Here, we address an enigma regarding sex differences in
MS. While women have more robust immune responses
and are more susceptible to MS and other autoimmune







Multiple Sclerosis Male vs. Healthy Control Male
Fig. 1 Gray matter atrophy and cortical thinning in female and male multiple sclerosis patients compared to healthy controls. a Maximum intensity
projections of the statistical parametric map of GM loss in all female MS patients compared to all female healthy controls (p < 0.05, FDR corrected)
overlaid on the SPM glass brain demonstrating significance clusters in the thalamus. b Sagittal, coronal, and axial sections through the statistical
parametric map of GM loss highlighting atrophy in the thalamus (sagittal view) overlaid on the CAT12 mean IXI template. c FreeSurfer cortical thinning
maps demonstrating no statistically-significant cortical thinning in female MS patients compared to healthy controls. d Maximum intensity projections
of the statistical parametric map of GM loss in all male MS patients compared to all male healthy controls (p < 0.05, FDR corrected) overlaid on the
SPM glass brain demonstrating significance clusters in the thalamus, putamen, the precuneus, and medial frontal cortex. e Sagittal, coronal, and axial
sections the statistical parametric map of GM loss highlighting atrophy in the thalamus (sagittal view), putamen (coronal view), and precuneus (axial
view) overlaid on the CAT12 mean IXI template. c FreeSurfer cortical thinning maps demonstrating statistically-significant cortical thinning in the
inferior parietal lobule (yellow arrow) and the superior and transverse occipital sulci (white arrow) in male MS patients compared to healthy controls
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Table 2 MRI measures.
MRI measures Healthy controls
Mean ± SD cc (n)
Multiple sclerosis
Mean ± SD cc (n)




Female 14.88 ± 1.10 (28) 13.91 ± 1.62 (52) − 0.98 − 6.8% p = 0.0021
q = 0.0070
g = 0.66




Female 9.50 ± 0.97 (28) 8.86 ± 1.17 (52) − 0.65 − 7.1% p = 0.010
q = 0.020
g = 0.58




Female 1088.3 ± 93.9 (28) 1029.9 ± 85.8 (52) − 58.4 − 5.5% p = 0.0086
q = 0.020
g = 0.66




Female 585.6 ± 51.1 (28) 555.6 ± 48.6 (52) − 30.0 − 5.2% p = 0.0139
q = 0.023
g = 0.61




Female 502.7 ± 52.1 (28) 474.3 ± 46.0 (52) − 28.4 − 5.8% p = 0.019
q = 0.027
g = 0.59
Male 577.7 ± 53.7 (17) 556.7 ± 44.1 (37) − 21.1 − 3.7% p = 0.17
q = 0.17
g = 0.44
FreeSurfer subcortical structure volumes and voxel-based morphometry (VBM) gray matter (GM), white matter (WM), and brain parenchymal fraction (BPF)
volumes from female and male MS patients and healthy controls. ‡ p is the uncorrected p value, q is the p value adjusted for multiple comparisons by controlling
the FDR, and g is the Hedge’s g value.
Table 3 Clinical measures
Clinical measures Female MS
Mean ± SD (n)
Male MS
Mean ± SD (n)
Absolute difference Percent difference ‡p value
q value
Hedge’s g
9-Hole peg test 19.6 ± 3.0 s (46) 22.3 ± 5.4 s (30) 2.7 s 13.1% p = 0.016
q = 0.048
g =0.66
Timed 25-foot walk 4.69 ± 1.0 s (45) 4.68 ± 1.7 s (27) − 0.01 s − 0.1% p = 0.98
q = 1.00
g = 0.001
Symbol digit modalities test 59.6 ± 14.7 (44) 55.8 ± 14.3 (32) − 3.8 − 6.5% p = 0.20
q = 0.60
g = 0.26
9-hole peg test (9HPT), timed 25-foot walk (T25FW), and symbol-digit modalities test (SDMT) from female and male MS patients. ‡ p is the uncorrected p value, q
is p value adjusted for multiple comparisons using the Bonferroni correction, and g is Hedge’s g
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diseases [6], being male is a risk factor for worse MS dis-
ability progression [5]. Since robust immune responses
and relapses are thought to contribute to neurodegener-
ation and disability progression, one would expect fe-
males and not males, to demonstrate worse MS
disability progression. However, since that is not the
case, the effect of sex appears to differ based on inflam-
mation versus neurodegeneration. We previously hy-
pothesized that MS men may have a more severe
neurodegenerative response to immune attack [5], and
addressed this in a MS preclinical model. Bone marrow
chimeras were used to separate effects of sex on the im-
mune system versus the CNS. The XX genotype had in-
creased pro-inflammatory immune responses [11], while
the XY genotype had a more severe neurodegenerative
response to a given immune attack [58].
Here, using independent and complementary ap-
proaches in clinical MS data, we found that MS men
demonstrated worse localized GM atrophy than MS
women, each as compared to their respective healthy
age- and sex-matched controls. This difference in re-
gional GM atrophy was not the result of MS males
having older age, longer disease duration, or more co-
morbidities as compared to MS females. Since GM atro-
phy is a sensitive putative biomarker for clinical
disability progression, these results provide insights into
previous observations that male sex confers increased
risk for disability progression [22–26]. Our results now
warrant a longitudinal study of regional GM atrophy
and disability progression rates over time in MS men
and MS women clinically matched at baseline.
When examining sex differences in regional brain atro-
phy in cross-sectional data, there are two critical factors.
First, one must include age- and sex-matched healthy con-
trols. Given the known major sex differences in overall
brain size and substructure volumes between healthy fe-
males and males for [15–18], each sex should be com-
pared to it respective HC. This major confound of the sex
difference in healthy brains is thereby removed by com-
paring MS female brains with healthy female brains and
MS male brains with healthy male brains. This will reveal
the effect of the MS disease process within each sex.
The second critical factor when examining sex differ-
ences in brain atrophy is to account for regional differ-
ences in the brain. Regional differences in gene
expression in CNS cells have been shown in both health
and disease [32–35], and regional differences in GM at-
rophy have been shown in MS [27–29]. The study of
whole GM atrophy can dilute and leave out significant
and potentially clinically eloquent regional GM atrophy
resulting in less sensitivity in detection. Evaluation of
whole cerebral cortical atrophy also pools together
highly disparate cortical regions based on known anat-
omy, gene expression, and function. Since sex hormones
and sex chromosomes would not act homogeneously
across cells in the entire brain, differential effects on
cells in specific CNS regions can be missed when exam-
ining whole GM or whole cerebral cortex. We previously
hypothesized that sex differences in neurodegeneration
in MS would be region-specific [33, 35, 36], and our data
here on sex differences in GM atrophy are consistent
with this hypothesis.
Aligned with a region-specific approach to sex differ-
ences in MS, a disability-specific approach is also war-
ranted. Previous studies have suggested that cognitive
disability in particular may be worse in males as com-
pared to females with MS [25], and differences in atro-
phy of major GM structures have been correlated with
cognitive disability [28, 54, 59–63]. Further studies are
needed comparing MS women and MS men using
biology-driven functional connectivity analysis [26, 35–
67] and voxel-wise mapping of localized GM atrophy
aligned with cognitive disability [30, 31]. Sex differences
in other disabilities such as in walking or vision, for ex-
ample, should also be mapped to contrast with cognitive
disability maps. Given the known sex differences in the
healthy brain [14–18], age- and sex-matched healthy
controls for these regional analyses are also required.
The importance of studying each sex independently in a
disease has been widely recognized [13, 14]. Our obser-
vation that 9HPT performance was impaired in MS
men, but not MS women, and that this clinical impair-
ment correlated with more atrophy of the thalamus in
MS men, but not MS women, underscores the import-
ance of studying each sex independently. Thalamic atro-
phy in early MS has been demonstrated previously [51–
54], although not in a sex-specific manner. With regard
to cortical thinning, this was previously observed in the
right superior and inferior parietal gyri of the Desikan-
Killiany Atlas [68] in a pooled dataset where the female
to male ratio was 1.6:1 [51]. Interestingly, there was sub-
stantial overlap with cortical thinning we observed in
the right intraparietal sulcus of the Destrieux Atlas [55]
in MS males (Fig. 1f).
A limitation of this study is the moderate sample sizes,
therefore future studies with larger sample sizes focusing
Table 4 Correlations
Correlations ‡All MS Female MS Male MS
Thalamus volume vs. 9HPT r = − 0.43
p = 0.00020
q = 0.0012
r = − 0.29
p = 0.052
q = 0.31
r = − 0.58
p = 0.0025
q = 0.015
Putamen volume vs. 9HPT r = − 0.35
p = 0.0026
q = 0.016
r = − 0.26
p = 0.083
q = 0.50
r = − 0.51
p = 0.0087
q = 0.052
Correlations between the 9-hole peg test (9HPT) and thalamus volume and
between the 9HPT and putamen volume in female and male MS patients. ‡ r
is Pearson’s r, p is the uncorrected p value, and q is p value adjusted for
multiple comparisons using the Bonferroni correction
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on correlations between clinical disabilities and regional
atrophy are warranted in each sex. Also, all the data here
are from a single cohort in Berlin, Germany. Whether
these results can be extrapolated to patients from other
MS cohorts warrants further investigation.
In MS, precision medicine requires targeting the most
responsive population with the most appropriate anti-
inflammatory treatment. In the future, neuroprotective
treatments must be designed with precision using a sex-
specific and CNS region-specific approach. This will ad-
vance the development of disability-specific neuropro-
tective treatments optimally tailored for each sex.
Finally, sex differences in regional GM atrophy shown
here in MS can serve as a roadmap for similar analyses
in other neurodegenerative diseases that exhibit sex dif-
ferences [14], such as Alzheimer’s disease [69, 70] and
Parkinson’s disease [71, 72].
Perspectives and significance
In summary, localized brain regions were found to
undergo worse atrophy in multiple sclerosis men than in
multiple sclerosis women, each as compared to their re-
spective healthy, age- and sex-matched controls. These re-
sults underscore the importance of studying sex
differences in each organ system, since MS women are
more susceptible to disease which is thought to reflect dif-
ferences in the immune system, but MS men have worse
disability progression which is thought to reflect differ-
ences in the central nervous system. Also, the approach
used here can be applied to other neurodegenerative dis-
eases characterized by a sex difference. Specifically,
mapping sex differences in brain regions during neurode-
generative diseases can serve as a foundation for future
neuroprotective treatment trials targeting these regions in
each sex.
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